Table 3.
Levels of NAEs in the hind paw (A) and midbrain (B) of rats receiving an acute or repeated treatment with URB597 (0.3 mg·kg−1) or vehicle prior to intraplantar injection of carrageenan
| A: Hind paw | |||
|---|---|---|---|
| Treatment | AEA (pmol g−1) median (range) | OEA (nmol g−1) median (range) | PEA (nmol g−1) median (range) |
| Acute vehicle + carrageenan | 5.22 (4.34–6.89) | 0.12 (0.04–0.19) | 0.12 (0.05–0.34) |
| Acute URB597 + carrageenan | 6.47 (4.26–11.15) | 0.09 (0.07–0.17) | 0.14 (0.06–0.30) |
| Repeated vehicle + carrageenan | 8.50 (1.45–12.28) | 0.15 (0.06–0.28) | 0.18 (0.14–0.24) |
| Repeated URB597 + carrageenan | 4.14 (1.38–14.14) | 0.15 (0.07–0.19) | 0.13 (0.08–0.19) |
| B: Midbrain | |||
|---|---|---|---|
| Treatment | AEA pmol g−1 median (range) | OEA nmol g−1 median (range) | PEA nmol g−1 median (range) |
| Acute vehicle + carrageenan | 16.41 (14.0–34.98) | 0.85 (0.72–1.34) | 1.34 (0.83–1.58) |
| Acute URB597 + carrageenan | 29.2 (18.6–44.78)* | 2.97 (0.98–3.36)* | 3.21(1.30–3.89)* |
| Repeated vehicle + carrageenan | 11.69 (8.84–22.69) | 0.70 (0.32–0.75) | 0.73 (0.38–1.01) |
| Repeated URB597 + carrageenan | 23.27 (15.57–51.58)* | 1.83 (0.51–2.67) | 2.28 (0.67–3.71)* |
Data are expressed as median and range, n= 9–13 rats per group. Comparisons between the effects of acute vehicle and acute URB597 or repeated vehicle and repeated URB597 were performed using a Mann–Whitney non-parametric test, *P < 0.05, significantly different from vehicle + carrageenan.